

Bassam Abdulkarim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11183405/publications.pdf>

Version: 2024-02-01

28
papers

1,478
citations

430874

18
h-index

552781

26
g-index

28
all docs

28
docs citations

28
times ranked

2575
citing authors

#	ARTICLE	IF	CITATIONS
1	Is Postoperative Radiotherapy Needed in the Management of Adult Craniopharyngiomas?. Canadian Journal of Neurological Sciences, 2022, , 1-7.	0.5	0
2	SYST-08. A phase II trial of concurrent Sunitinib, Temozolomide and Radiation Therapy followed by adjuvant Temozolomide for newly diagnosed Glioblastoma patients with an unmethylated MGMT gene promoter (A01-M121-11A, McG1132). Neuro-Oncology Advances, 2021, 3, iv10-iv10.	0.7	0
3	PTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative Disease. JNCI Cancer Spectrum, 2020, 4, pkz063.	2.9	17
4	SABR-BRIDGE: Stereotactic Ablative Radiotherapy Before Resection to Avoid Delay for Early-Stage Lung Cancer or Oligometastases During the COVID-19 Pandemic. Frontiers in Oncology, 2020, 10, 580189.	2.8	19
5	Integration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma. Cancers, 2019, 11, 1148.	3.7	41
6	Predicting the Gene Status and Survival Outcome of Lower Grade Glioma Patients With Multimodal MRI Features. IEEE Access, 2019, 7, 75976-75984.	4.2	25
7	An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy. Nature Communications, 2019, 10, 2139.	12.8	46
8	Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation. Frontiers in Oncology, 2019, 9, 374.	2.8	132
9	Novel Radiomic Features Based on Joint Intensity Matrices for Predicting Glioblastoma Patient Survival Time. IEEE Journal of Biomedical and Health Informatics, 2019, 23, 795-804.	6.3	65
10	CUX1 stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the mono-alkylating agent temozolomide. Neuro-Oncology, 2018, 20, 484-493.	1.2	32
11	Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Neuro-Oncology, 2018, 20, 236-248.	1.2	103
12	Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings. Breast Cancer Research, 2018, 20, 140.	5.0	25
13	Prediction of survival with multi-scale radiomic analysis in glioblastoma patients. Medical and Biological Engineering and Computing, 2018, 56, 2287-2300.	2.8	69
14	Response to stereotactic ablative radiotherapy in a novel orthotopic model of non-small cell lung cancer. Oncotarget, 2018, 9, 1630-1640.	1.8	7
15	A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2017, 97, 487-494.	0.8	40
16	Predicting survival time of lung cancer patients using radiomic analysis. Oncotarget, 2017, 8, 104393-104407.	1.8	54
17	Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells. Cancer Biology and Therapy, 2016, 17, 390-399.	3.4	6
18	Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution. Radiation Oncology, 2015, 10, 106.	2.7	15

#	ARTICLE	IF	CITATIONS
19	Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e71987.	2.5	52
20	O(6)-Methylguanine-DNA Methyltransferase Is a Novel Negative Effector of Invasion in Glioblastoma Multiforme. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2440-2450.	4.1	21
21	The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 187-194.	2.5	71
22	MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. <i>Neuro-Oncology</i> , 2010, 12, 822-833.	1.2	74
23	Î²1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. <i>Cancer Research</i> , 2009, 69, 8620-8628.	0.9	77
24	Cidofovir Administered with Radiation Displays an Antiangiogenic Effect Mediated by E6 Inhibition and Subsequent TP53-Dependent VEGF Repression in HPV18+ Cell Lines. <i>Radiation Research</i> , 2006, 166, 600-610.	1.5	9
25	Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5658-5663.	1.6	288
26	Antiviral agent Cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. <i>Oncogene</i> , 2003, 22, 2260-2271.	5.9	50
27	Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. <i>Oncogene</i> , 2002, 21, 2334-2346.	5.9	121
28	Antiviral approaches for cancers related to Epstein-Barr virus and human papillomavirus. <i>Lancet Oncology</i> , The, 2001, 2, 622-630.	10.7	19